TODAY’S COVID-19 INFORMATION

Monday, April 4, 2022

NEW: Epidemiology Data and Notes

NEW: BA.2 Subvariant Update

NEW: Employee Eligibility for Second Booster

NEW: Denver Health Patient Eligibility for Second Booster

NEW: Changes to Outpatient COVID-19 Therapies, Starting Wednesday April 6th

What You Need to Know

NEW: Epidemiology Data and Notes

As of 6:30 AM Denver Health has 4 COVID-19 Patients, 3 are on the Floor, 1 in the ICU.

NEW: BA.2 Subvariant Update

The SARS-CoV-2 Omicron subvariant BA.2 continues to spread and now accounts for over half of new infections in the United States. In Colorado, it is estimated that 30% of cases in mid-March were caused by BA.2 with an increasing trend. Although the BA.2 subvariant appears to be more infectious than the original Omicron variant (BA.1), the incidence of both COVID-19 cases and hospitalizations in Denver County continue to be low.

This trend is also apparent in the graph above, where Denver Health has seen a steady decline in COVID-19 positive patients.

NEW: Employee Eligibility for Second Booster

Despite the emergence of the BA.2 subvariant, COVID-19 vaccines continue to provide strong protection against severe illness.

The FDA and CDC recently released the following guidance for a second booster dose in certain populations to further increase protection:

  • People aged 12 years and older who are moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA (Pfizer or Moderna) COVID-19 vaccine at least four months after the first booster dose.

  • Adults aged 50 years and older who are not moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA (Pfizer or Moderna) COVID-19 vaccine at least four months after the first booster dose.

  • Adults aged 18-49 years who are not moderately or severely immunocompromised and who received the J&J COVID-19 vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA (Pfizer or Moderna) COVID-19 vaccine at least four months after the first J&J booster dose

If you fall under one of these categories, you are now eligible to schedule your booster by going into your MyChart account. Please make sure to bring your COVID vaccine card to your appointment. As always, if you have questions about receiving a second booster please contact your physician.

NEW: Denver Health Patient Eligibility for Second Booster

As of today, April 4, 2022 Denver Health patients have access to go into their MyChart accounts and sign up for their second booster. Patients may also call the appointment center or ask their provider to schedule a second booster.

Patients are considered eligible if they fall under the following categories:

  • People aged 12 years and older who are moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA (Pfizer or Moderna) COVID-19 vaccine at least four months after the first booster dose.

  • Adults aged 50 years and older who are not moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA (Pfizer or Moderna) COVID-19 vaccine at least four months after the first booster dose.

  • Adults aged 18-49 years who are not moderately or severely immunocompromised and who received the J&J COVID-19 vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA (Pfizer or Moderna) COVID-19 vaccine at least four months after the first J&J booster dose

NEW: Changes to Outpatient COVID-19 Therapies

Denver Health has been working with our ambulatory sites that administer monoclonal antibodies and will switch from sotrovimab to bebtelovimab on Wednesday, April 6th.

There are no changes in who is eligible for outpatient monoclonal antibody therapy. However, because there is a limited amount of clinical data for bebtelovimab, use of oral nirmatrelvir-ritonavir (Paxlovid) should be considered the treatment of choice for eligible outpatients with mild to moderate COVD-19.

You can review the DH Treatment Guideline for details about prescribing and which pharmacies this can be dispensed from.

As a reminder:

  • Bebtelovimab, which retains activity against BA.2, is now the recommended monoclonal antibody for the treatment of mild to moderate COVID-19.

  • Use of sotrovimab is no longer recommended due to reduced activity against BA.2.

Denver Health COVID-19 Resources:

Updated Denver Health Masking Policy FAQ

Quarantine Instructions for Vaccine-exempt Employees

Mandatory COVID-19 Vaccine FAQs for Staff

Denver Health Pediatric Vaccination One-Pager

Denver Health Pediatric YouTube Video

Did this answer your question?